All In Biotech

Drug Trial Radar · NCT05773820

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of WJB001 Capsules in Dose Escalation, Dose Expansion, and Efficacy Expansion in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

63

Actual

Start

May 5, 2023

Primary completion

Dec 31, 2027

Study completion Jul 31, 2028

Sponsor

Sponsor type
Industry
Collaborators
Sponsor GmbH
First posted
Mar 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II study to evaluate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJB001 capsules in patients with advanced solid tumors, including dose escalation phase, dose expansion phase and cohort expansion phase.The study includes screening, treatment and follow-up periods. In the Dose Escalation phase:Accelerated titration (the first two dose groups) and "BOIN" combination (the subsequent dose group) were used for dose escalation. In the Dose Expansion phase:Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D. In the Efficacy Expansion phase:The preliminary plan of Efficacy expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts.

Conditions

  • Advanced Solid Tumors

Interventions

  • WJB001Drug

    WJB001 Capsules:160mg(or othe dosages),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies,Every 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1.Dose limited toxicity (DLT)Time frame: 21d
  2. 2.Adverse event (AE)Time frame: 3 years
  3. 3.Serious adverse event (SAE)Time frame: 3 years
  4. 4.Maximum tolerated dose (MTD)Time frame: 2 years
  5. 5.Recommended phase II dose (RP2D)Time frame: 2 years
  6. 6.Objective response rate(ORR)Time frame: 3 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Fuxin People's Hospital (Fuxin Women and Children's Medical Center)

    Fuxin, Liaoning, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi’an, Shanxi, China

  • Henan Cancer Hospital

    Henan, Zhenzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.